Literature DB >> 18958768

Thyroid function after hysterosalpingography using an oil-soluble iodinated contrast medium.

Keiko Mekaru1, Shigeru Kamiyama, Hitoshi Masamoto, Kaoru Sakumoto, Yoichi Aoki.   

Abstract

BACKGROUND: The objective of the present study was to evaluate the effect of an oil-soluble iodinated contrast medium (lipiodol) for hysterosalpingography (HSG) on thyroid function.
METHODS: In 214 of 528 women with infertility examined by HSG using lipiodol between 1996 and 2006 at our institution, serum free thyroxine (FT4) and thyrotropin-stimulating hormone (TSH) were measured before and several months after HSG.
RESULTS: The average age of the women was 34.5 +/- 4.6 years and their average infertility period was 2.9 +/- 2.5 years (mean+/-standard deviation). The 214 patients were divided into three groups based on the results of thyroid function before HSG: 180 in euthyroid, 28 in subclinical hypothyroidism and 13 in subclinical hyperthyroidism. The number of patients in the subclinical hypothyroidism group who developed hypothyroidism after HSG (ten of 28) was significantly higher than that of the euthyroid group (four of 180). Thyroid hormone replacement was required in three patients from the subclinical hypothyroidism group 1, 2 and 5 months after HSG.
CONCLUSIONS: We conclude that thyroid function should be monitored closely after HSG using lipiodol to detect the development of hypothyroidism, particularly in patients with subclinical hypothyroidism, and TSH and FT4 measurements should be performed before HSG to identify patients at risk for hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18958768     DOI: 10.1080/09513590802246364

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  9 in total

Review 1.  Iodine-induced thyroid dysfunction.

Authors:  Angela M Leung; Lewis E Braverman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-10       Impact factor: 3.243

2.  2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction.

Authors:  Tomasz Bednarczuk; Thomas H Brix; Wolfgang Schima; Georg Zettinig; George J Kahaly
Journal:  Eur Thyroid J       Date:  2021-06-16

Review 3.  Risk factors of subclinical hypothyroidism and the potential contribution to miscarriage: A review.

Authors:  Shuhei So; Fumiko Tawara
Journal:  Reprod Med Biol       Date:  2020-03-18

4.  The Impact of Preconceptional Hysterosalpingography with Oil-based Contrast on Maternal and Neonatal Iodine Status.

Authors:  Rongrong Li; Wei Chen; Yanping Liu; Liangkun Ma; Ling Qiu; Jianhua Han; Rui Li
Journal:  Reprod Sci       Date:  2021-06-02       Impact factor: 3.060

Review 5.  Radiographic and magnetic resonances contrast agents: Essentials and tips for safe practices.

Authors:  Mohamed R Nouh; Mohamed A El-Shazly
Journal:  World J Radiol       Date:  2017-09-28

6.  Thyroid function in neonates conceived after hysterosalpingography with iodinated contrast.

Authors:  N van Welie; I Roest; M Portela; J van Rijswijk; C Koks; C B Lambalk; K Dreyer; B W J Mol; M J J Finken; V Mijatovic
Journal:  Hum Reprod       Date:  2020-05-01       Impact factor: 6.918

7.  Hysterosalpingography with Oil-Soluble Contrast Medium Does Not Increase Newborn Hypothyroidism.

Authors:  Divya M Mathews; Jane M Peart; Neil P Johnson; Robert G Sim; Natasha L Heather; Dianne Webster; Susannah O'Sullivan; Paul L Hofman
Journal:  Int J Endocrinol       Date:  2022-02-22       Impact factor: 3.257

8.  Complications after hysterosalpingography with oil- or water-based contrast: results of a nationwide survey.

Authors:  Inez Roest; Nienke van Welie; Velja Mijatovic; Kim Dreyer; Marlies Bongers; Carolien Koks; Ben Willem Mol
Journal:  Hum Reprod Open       Date:  2020-01-15

9.  Hyperthyroidism secondary to hysterosalpingography: an extremely rare complication: A case report.

Authors:  Guotao Ma; Rui Mao; Haixin Zhai
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.